Thursday, 29 October 2026European Markets

Monetary Policy

2 articles

ECB Keeps Dovish Stance as Fed Holds Restrictive Rates, EUR/USD Pressure Mounts

ECB Keeps Dovish Stance as Fed Holds Restrictive Rates, EUR/USD Pressure Mounts

The European Central Bank maintains its gradual rate-cutting path while the Federal Reserve signals prolonged restrictive policy, driving currency divergence. Fed's Jeff Schmid warns further rate cuts risk persistent inflation, contrasting sharply with ECB Vice President Luis de Guindos citing positive inflation news. The policy split widens the 2-year US-German yield spread, threatening capital outflows from European markets.

ViaNews Editorial Team (Europe)•
Federal Reserve signals slower rate cuts in 2026 as labor market stays resilient

Federal Reserve signals slower rate cuts in 2026 as labor market stays resilient

Fed governors Philip Jefferson and Chris Waller indicated the central bank will slow its pace of rate cuts in 2026, citing strong employment data and rates still restricting economic activity. The shift creates diverging prospects for European financial markets tied to dollar movements and transatlantic capital flows.

ViaNews Editorial Team (Europe)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,503 source documents archived
Query this data → isubstrate.com